4883 — Modalis Therapeutics Share Price
0.000.00%
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.08 | ||
| Price to Tang. Book | 2.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -131.82% | ||
| Return on Equity | -110.69% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 644.5 | 342 | 1.1 | 40.5 | n/a | 1,650 | 2,050 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Directors
- Haru Morita PRE (51)
- Naoki Kobayashi CFO
- Tetsuya Yamagata SVP
- Toshio Furuta IND (58)
- Joseph McCracken IND (67)
- Osamu Nureki IND (54)
- Miyuki Shimane IND (66)
- Teruhisa Tajima IND (49)
- Hideki Takeda IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 14th, 2016
- Public Since
- August 3rd, 2020
- No. of Shareholders
- 13,576
- No. of Employees
- 37
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 36,795,143
- Address
- 4F, CHUO-KU, 103-0023
- Web
- https://www.modalistx.com/
- Phone
- +81 368224584
- Auditors
- KPMG AZSA LLC
Upcoming Events for 4883
Dividend For 4883.T - 0.0000 JPY
Similar to 4883
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the Modalis Therapeutics share price?
As of Today at 19:14 UTC, shares in Modalis Therapeutics are trading at ¥78. This share price information is delayed by 15 minutes.
How has the Modalis Therapeutics share price performed this year?
Shares in Modalis Therapeutics last closed at ¥78 and the price had moved by -74.26% over the past 365 days. In terms of relative price strength the Modalis Therapeutics share price has underperformed the Nikkei 225 Index by -80.63% over the past year.
What are the analyst and broker recommendations for Modalis Therapeutics?
The overall consensus recommendation for Modalis Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Modalis Therapeutics dividend yield?
Modalis Therapeutics does not currently pay a dividend.
Does Modalis Therapeutics pay a dividend?
Modalis Therapeutics does not currently pay a dividend.
When does Modalis Therapeutics next pay dividends?
Modalis Therapeutics does not currently pay a dividend.
How do I buy Modalis Therapeutics shares?
To buy shares in Modalis Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Modalis Therapeutics?
As of the previous close price of ¥78, shares in Modalis Therapeutics had a market capitalisation of ¥3bn.
Where are Modalis Therapeutics shares listed?
Here are the trading details for Modalis Therapeutics:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4883
What kind of share is Modalis Therapeutics?
Based on an overall assessment of its quality, value and momentum Modalis Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Modalis Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Modalis Therapeutics is ¥900. That is 1053.85% above the last closing price of ¥78.
Analysts covering Modalis Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
What is the trend in the Modalis Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Modalis Therapeutics. Over the past six months, its share price has underperformed the Nikkei 225 Index by -54.64%.
As of the last closing price of ¥78, shares in Modalis Therapeutics were trading -44.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Modalis Therapeutics PE Ratio?
The Modalis Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Modalis Therapeutics?
Modalis Therapeutics' management team is headed by:
- Haru Morita - PRE
- Naoki Kobayashi - CFO
- Tetsuya Yamagata - SVP
- Toshio Furuta - IND
- Joseph McCracken - IND
- Osamu Nureki - IND
- Miyuki Shimane - IND
- Teruhisa Tajima - IND
- Hideki Takeda - IND